Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía Morales, Victoria 
dc.contributor.authorGonzález Acedo, Anabel
dc.contributor.authorMelguizo-Rodríguez, Lucía
dc.contributor.authorPardo-Moreno, Teresa
dc.contributor.authorCostela-Ruiz, Víctor Javier
dc.contributor.authorMontiel-Troya, María
dc.contributor.authorRamos-Rodríguez, Juan José
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2022-03-15T11:01:22Z
dc.date.available2022-03-15T11:01:22Z
dc.date.issued2021-12
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/10498/26432
dc.description.abstractAlzheimer's disease (AD) is the most common cause of dementia. It is characterized by cognitive decline and progressive memory loss. The aim of this review was to update the state of knowledge on the pathophysiological mechanisms, diagnostic methods and therapeutic approach to AD. Currently, the amyloid cascade hypothesis remains the leading theory in the pathophysiology of AD. This hypothesis states that amyloid-beta (A beta) deposition triggers a chemical cascade of events leading to the development of AD dementia. The antemortem diagnosis of AD is still based on clinical parameters. Diagnostic procedures in AD include fluid-based biomarkers such as those present in cerebrospinal fluid and plasma or diagnostic imaging methods. Currently, the therapeutic armory available focuses on symptom control and is based on four pillars: pharmacological treatment where acetylcholinesterase inhibitors stand out; pharmacological treatment under investigation which includes drugs focused on the control of A beta pathology and tau hyperphosphorylation; treatment focusing on risk factors such as diabetes; or nonpharmacological treatments aimed at preventing development of the disease or treating symptoms through occupational therapy or psychological help. AD remains a largely unknown disease. Further research is needed to identify new biomarkers and therapies that can prevent progression of the pathology.es_ES
dc.description.sponsorshipL.M.-R. and J.J.R.-R. are funded by P20-01293 from Junta de Andalucia, Spain. J.J.R.-R. is additionally funded by PECART-0096-2020 from Junta de Andalucia, Spain and PID2020-117544RB-100 from the Ministry of Science and Innovation, Spain.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines 2021, 9(12), 1910es_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectsenile plaqueses_ES
dc.subject-amyloid proteines_ES
dc.subjectdiagnosises_ES
dc.subjectbiomarkeres_ES
dc.subjecttreatmentes_ES
dc.subjectacetylcholinesterase inhibitorses_ES
dc.subjectimmunotherapyes_ES
dc.titleCurrent Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomedicines9121910
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117544RB-I00/ES/NANOBOMBA TERMOFORETICA DIRIGIDA Y CELULAS CAR MONITORIZADAS POR NANOPARTICULAS COMO TERAPIA INMUNOLOGICA COMBINADA/es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional